Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Yeah it's not a trial though, is it?
Intranasal foralumab was well-tolerated with no adverse reactions or laboratory abnormalities after 6 months of therapy and the patient chose to remain on therapy
Data show sustained inhibition of microglial activation as assessed by Positron Emission Tomography (PET) along with downregulation of pro-inflammatory cytokines associated with brain inflammation, as well as stabilization of disease as measured by clinical assessments
Based on these observations the FDA has allowed a second patient to receive intranasal foralumab therapy under a separate Single-Patient Expanded Access IND (SPIND)
Tiziana to hold Key Opinion Leader (KOL) event to discuss the data on March 14th, 2022, 11 a.m. ET
August 2020 raised $57m
Finished part 1 of the Brazil Covid trial then nothing since then but withdrawn trials or amended protocols.
How can people seriously think things are going well here?
Right but they withdrew the Covid trial and now I can see also that they have also withdrawn the MS trial they put up last August
https://clinicaltrials.gov/ct2/show/NCT05029609?spons=Tiziana&draw=2&rank=1
What are they doing? Presenting an anecdote from 1 patient in a compassionate use program as if this can somehow make up for not running a trial.
They raised $57m and have not run a single trial since then.
What have they done with the cash???
Today, #TLSA announced some very exciting news!!
We reported positive clinical data, from a Secondary Progressive Multiple Sclerosis (SPMS) patient treated for six months with intranasally administered foralumab.
https://tizianalifesciences.com/news-item?s=2022-03-10-tiziana-announces-positive-clinical-data-from-a-secondary-progressive-multiple-sclerosis-patient-treated-for-six-months-with-intranasally-administered-foralumab-a-fully-human-anti-cd3-monoclonal-antibody
just as important in sp rally is the volume traded so far today, 7m shares
hopefully thats's a shed load of new investors in addition to the day traders
GLA
live price $1.03. up 43 percent
Only annoying thing for me is the other day thier is the threat because been under $1 and might get kicked out of the exchange, then out of the blue, well what do you know!
Pathetic, really is.
Yeah Covid is far from done.
You would have thought they would have mentioned it either way
Looks that way SJ1
Recruiting status: Withdrawn
Info: Withdrawn: The study stopped early, before enrolling its first participant.
I guess Covid is yesterdays news. It was 12 months in the build up though!!
BB
Strange they didn't say anything about it
https://clinicaltrials.gov/ct2/show/NCT04983446?spons=Tiziana&draw=2&rank=3
Howard Weiner, MD, Director of the Multiple Sclerosis Program at BWH and Chairman of Tiziana’s Scientific Advisory Board, commented, “The potential for intranasally administered foralumab to suppress microglial activation is a novel and well-tolerated immunologic approach to potentially treat SPMS, a form of MS that currently has no effective treatment. We are extremely pleased with the tolerability of intranasal foralumab and with the positive clinical and PET imaging responses observed after completion of six months of dosing in the first patient. We look forward to treating additional patients to fill a major unmet need for the treatment of SPMS.”
Tanuja Chitnis, MD, Principal Investigator and Professor of Neurology at Harvard Medical School (HMS) and senior neurologist at BWH and Massachusetts General Hospital added, “New treatments for progressive MS are urgently needed. Intranasal foralumab could revolutionize treatment for this disabling form of disease.”
Tarun Singhal, MD, Director of PET Imaging Program in Neurologic Diseases, associate neurologist and nuclear medicine physician at BWH commented, “The longitudinal PET imaging results suggesting sustained reduction in microglial activation in the first SPMS patient treated with foralumab, are highly encouraging. We are very excited to further investigate the effects of foralumab in SPMS patients using additional quantitative PET approaches.”
About the Role of Microglial Activation in Neurodegenerative Diseases
Activation of microglia is a hallmark of brain inflammation. It is believed to play an important role in the pathway leading to neuronal cell death in several neurodegenerative diseases including Parkinson’s disease, Alzheimer’s disease, prion diseases, multiple sclerosis and HIV-dementia. The chronic activation of microglia causes neuronal damage through the release of cytotoxic molecules such as pro-inflammatory cytokines, reactive oxygen intermediates, proteinases and complement proteins. Suppression of microglial inflammation has been considered as an important strategy in neurodegenerative disease therapy.
BB
'In addition to being well-tolerated, both biological and clinical improvements were seen in this patient using Tiziana’s novel immunotherapy technology, which, importantly overcame the challenge of delivering this antibody across the blood-brain barrier to affect immunomodulation in the brain.'
BB
Posted 30 seconds too early.
Now up 36% and $1 hit.
Up 32% pre-market over the pond. Would be nice to see that stick.
The might even hit the magic $1
No option but to sit tight.
A decent enough Form 6-K just issued anyway. Some positive data.
Part of me didn’t want HL to catch up…..
Painful reading but still bullish. I’ve not heard anything to say the science is not still on track (although granted slightly delayed timetable). The end game is still a potential game changer and could be massive.
Sitting tight and look forward to the March data on the MS patient
You can trade on the HL app, you just have to do your first TLSA trade on the HL website then the app will recognise TLSA.
Thank you Vista for pointing that out.. Let us see what the next few days and weeks bring us.
Lazypunter, I think the HL figures are correct. They have reduced your holding by 50% so that they can use the TLSA share price converted to pence. When you sell any shares now it will be TLSA and by telephone dealing with HL only.
Guys.
The fact that it is showing on HL is a bright step, even if the figures are wrong. We need SHAKIRHAN to tell us what he thinks, as he knows far more than anyone else on this BB..
Feeling a bit robbed now.Presume it's tradeable now on h/l..?
The HL consolidation has been carried out to TLSA.
So equals current 75 cents stateside.Is there a 2 for 1 deduction to be made as well then ?..forgot about the halving of value !